美国的印地安毒品制造商在安全和质量问题上召回产品。 Indian drugmakers in the U.S. recall products over safety and quality issues, per FDA.

美国监管机构报告说,由于制造问题,印度在美国市场的制药公司多次召回产品. U.S. regulators have reported multiple recalls by Indian pharmaceutical companies operating in the U.S. market due to manufacturing problems. Glenmark、Granules India、Sun Pharma、Zydus 和 Unichem 正在召回各种产品，从痤疮凝胶到苯丙胺胶囊和成像试剂盒，原因包括砂砾质地、杂质、降解和标签错误等问题。 Glenmark, Granules India, Sun Pharma, Zydus, and Unichem are recalling various products—ranging from acne gel to amphetamine capsules and imaging kits—over issues like gritty texture, impurity, degradation, and labeling errors. 根据风险,FDA将这些产品归类为I至III类,这些公司自愿开始召回. Recalls, classified as Class I to III by the FDA based on risk, were initiated voluntarily by the companies. 食品药品管理局指出,印度在美国境外拥有美国批准最多的毒品制造设施。 The FDA notes India has the most U.S.-approved drug manufacturing facilities outside the U.S.